AUTL:NASDAQ, Autolus Therapeutics plc

AUTL stock overview

Autolus Therapeutics plc (AUTL:NASDAQ) closed at $1.53 on October 26, 2026, down 0.65% on the day. The stock trades 40.7% below its 52-week high of $2.58 and 30.2% above its 52-week low of $1.18. Over the past year, it gained 0.7%. Autolus Therapeutics plc is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).

Key figures

Price

$1.53

Day change

-0.65%

Volume

1,236,498

Average volume

2,214,057

Market cap

407M+

52-week range

$1.18 – $2.58

50-day average

$1.99

200-day average

$1.67

Price action over the past year

In 252 trading sessions since October 24, 2025, AUTL closed higher on 112 days (44%). Its best day was August 3, 2026 (+22.15%) and its worst was January 12, 2026 (-17.13%). The stock moved 10% or more in a single session 10 times. It opened at least 5% above the previous day's high 2 times.

Recent signals

• Oct 26, 2026: News catalyst: Earnings (News Catalysts scanner)
• Oct 23, 2026: Hit a new 1-Month Low of $1.54 (New Highs/Lows scanner)
• Oct 23, 2026: Trading sideways between $1.54 and $1.74 over 14 days (Sideways scanner)
• Aug 19, 2026: Spiked to $2.58 on 7M+ shares (Spikes scanner)

AUTL news

• Oct 26, 2026: Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
• Oct 5, 2026: All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy
• Oct 5, 2026: Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
• Sep 12, 2026: AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn't In The Black
• Sep 9, 2026: Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
• Aug 14, 2026: European Equities Traded in the US as American Depositary Receipts Track Lower in Friday Trading
• Aug 13, 2026: European Equities Traded in the US Rise in Thursday Trading
• Aug 11, 2026: European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

About Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company. It is engaged in the development of next-generation programmed T cell therapies for the treatment of cancer. The company's pipeline includes AUTO1, AUTO2, AUTO3, AUTO4, and AUTO6.

Similar stocks

• ALLO:NASDAQ
• RGNX:NASDAQ
• EDIT:NASDAQ
• FENC:NASDAQ
• ENTX:NASDAQ
• XFOR:NASDAQ
• AGEN:NASDAQ
• SLDB:NASDAQ

Find more stocks like AUTL with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.